Non-Proteasomal Urine Activity in Bladder Cancer.
bladder cancer
chromogenic substrates
protease profiling
urine proteases
Journal
Chemistry & biodiversity
ISSN: 1612-1880
Titre abrégé: Chem Biodivers
Pays: Switzerland
ID NLM: 101197449
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
12
2020
accepted:
25
01
2021
pubmed:
27
1
2021
medline:
9
7
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
Bladder cancer (BC) is the sixth common cancer in the world, characterized by high recurrent rate and poor prognosis. In most cases is asymptomatic and it can take years until symptoms develop. What is more, diagnosed patients need regular re-examinations which are invasive and expensive. Here, we used chromogenic substrates for the qualitative determination of specific activity of urine enzymes in healthy and bladder cancer patients. The peptide ABZ-Met-Lys-Val-Trp-ANB-NH
Identifiants
pubmed: 33496019
doi: 10.1002/cbdv.202000981
doi:
Substances chimiques
Peptides
0
Peptide Hydrolases
EC 3.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2000981Informations de copyright
© 2021 Wiley-VHCA AG, Zurich, Switzerland.
Références
A. M. Kamat, N. M. Hahn, J. A. Efstathio, S. P. LerneR, P. U. Malmström, W. Choi, C. C. Guo, Y. Lotan, W. Kassouf, ‘Bladder cancer’, Lancet 2016, 388, 2796-2810.
Y. Zhang, ‘Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens’, J. Environ. Sci. Health Part C 2013, 31, 287-304.
D. S. Kaufman, W. U. Shipley, A. S. Feldman, ‘Bladder cancer’, Lancet 2009, 374, 239-249.
P. Kutwin, T. Konecki, E. M. Borkowska, M. Traczyk-Borszyńska, Z. Jabłonowski, ‘Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis’, Cent. Eur. J. Urol. 2018, 71, 177-185.
M. C. Oliveira, H. R. Caires, M. J. Oliveira, A. Fraga, M. H. Vasconcelos, R. Ribeiro, ‘Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles’, Cancers 2020, 12, 1400.
B. Planz, E. Jochims, T. Deix, H. P. Caspers, G. Jakse, A. Boecking, ‘The role of urinary cytology for detection of bladder cancer’, Eur. J. Surg. Oncol. 2005, 31, 304-308.
M. Babjuk, M. Burger, E. M. Compérat, P. Gontero, A. H. Mostafid, J. Palou, B. W. G. van Rhijn, M. Rouprêt, S. F. Shariat, R. Sylvester, R. Zigeuner, O. Capoun, D. Cohen, J. L. D. Escrig, V. Hernández, B. Peyronnet, T. Seisen, V. Soukup, ‘European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update’, Eur. Urol. 2019, 76, 639-657.
M. F. Botteman, C. L. Pashos, A. Redaelli, B. Laskin, R. Hauser, ‘The health economics of bladder cancer: a comprehensive review of the published literature’, PharmacoEconomics 2003, 21, 1315-1330.
T. G. Rosano, T. A. Swift, L. W. Hayes, ‘Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma’, Clin. Chem. 1991, 37, 1854-1867.
S. Jeong, Y. Park, Y. Cho, Y. R. Kim, H. S. Kim, ‘Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer’, Clin. Chim. Acta 2012, 414, 93-100.
J. Zoidakis, M. Makridakis, P. G. Zerefos, V. Bitsika, S. Esteban, M. Frantzi, K. Stravodimos, N. P. Anagnou, M. G. Roubelakis, M. Sanchez-Carbayo, A. Vlahou, ‘Profilin 1 is a potential biomarker for bladder cancer aggressiveness’, Mol. Cell. Proteomics 2012, 11, M111.009449.
C. Li, H. Li, T. Zhang, J. Li, L. Liu, J. Chang, ‘Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis’, Biochem. Biophys. Res. Commun. 2014, 446, 1047-1052.
F. Darwiche, D. J. Parekh, M. L. Gonzalgo, ‘Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise’, Indian J. Urol. 2015, 31, 273-282.
M. Nagata, S. Muto, S. Horie, ‘Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes’, Dis. Markers 2016, 2016, 8205836.
M. Majetschak, L. T. Sorell, ‘Immunological methods to quantify and characterize proteasome complexes: development and application’, J. Immunol. Methods 2008, 334, 91-103.
C. J. Rosser, M. Chang, Y. Dai, Y. S. Ross, L. Mengual, A. Alcaraz, S. Goodison, ‘Urinary protein biomarker panel for the detection of recurrent bladder cancer’, Cancer Epidemiol. Biomarkers Prev. 2014, 23, 1340-1345.
N. Gruba, M. Wysocka, M. Brzezińska, D. Dębowski, M. Sieńczyk, E. Gorodkiewicz, T. Guszcz, C. Czaplewski, K. Rolka, A. Lesner, ‘Bladder cancer detection using a peptide substrate of the 20S proteasome’, FEBS J. 2016, 283, 2929-2948.
J. S. Dudani, A. D. Warren, S. N. Bhatia, ‘Harnessing protease activity to improve cancer care’, Ann. Rev. Cancer Biol. 2018, 2, 353-376.
M. Egeblad, Z. Werb, ‘New functions for the matrix metalloproteinases in cancer progression’, Nat. Rev. Cancer 2002, 2, 161-74.
K. Kessenbrock, V. Plaks, Z. Werb, ‘Matrix metalloproteinases: regulators of the tumor microenvironment’, Cell 2010, 141, 52-67.
O. C. Olson, J. A. Joyce, ‘Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response’, Nat. Rev. Cancer 2015, 15, 712-729.
C. A. Borgoño, E. P. Diamandis, ‘The emerging roles of human tissue kallikreins in cancer’, Nat. Rev. Cancer 2004, 4, 876-890.
C. López-Otín, L. M. Matrisian, ‘Emerging roles of proteases in tumor suppression’, Nat. Rev. Cancer 2007, 7, 800-808.
G. Heine, M. Raida, W. G. Forssmann, ‘Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry’, J. Chromatogr. A 1997, 776, 117-124.
J. Adachi, C. Kumar, Y. Zhang, J. V. Olsen, M. Mann, ‘The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins’, Genome Biol. 2006, 7, R80.
J. J. D′Costa, J. C. Goldsmith, J. S. Wilson, R. T. Bryan, D. G. Ward, ‘A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer’, Bladder Cancer 2016, 2, 301-317.
J. B. Henry, ‘Clinical Diagnosis and Management by Laboratory Methods’, WB Saunders Company, Philadelphia, PA, 1979, 1, 60.
A. Furka, F. Sebestyén, M. Asgedom, G. Dibó, ‘General method for rapid synthesis of multicomponent peptide mixtures’, Int. J. Pept. Protein Res. 1991, 37, 487-93.